Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 79

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 79
---
 of Enfusion. Additionally, the Special Meeting may be adjourned if
sufficient votes are cast in favor of the Adjournment Proposal whether or not there is a quorum.

Notice need not be given of any
adjourned meeting if the time and place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present and vote at such adjourned meeting are announced at the meeting at which the
adjournment is taken unless the adjournment is for more than 30 days, in which case a notice of the adjourned meeting will be given to each stockholder of record entitled to vote at the meeting. If, after any adjournment, a new record date for the
stockholders entitled to vote is fixed for any adjourned meeting, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be
present and vote at such adjourned meeting must be given to each stockholder of record entitled to vote at the meeting.

Questions and Additional Information

You may contact Enfusion’s proxy solicitor, Innisfree, 501 Madison Avenue, 20
Floor, New York City, NY 10022, with any questions about the Special Meeting, the Transactions, the proposals or this Proxy Statement/Prospectus, if you would like additional copies of the Proxy Statement/Prospectus, if you need to obtain proxy
cards or other information related to the proxy solicitation or if you need help submitting a proxy or voting your shares of Enfusion Common Stock or Enfusion Class B Common Stock. Enfusion Stockholders may call toll-free at (877) 750-0637, and banks and brokers may call collect at (212) 750-5833.

49

PROPOSAL 1: THE MERGER AGREEMENT PROPOSAL

As discussed throughout this Proxy Statement/Prospectus, Enfusion is asking its stockholders to approve the Merger Agreement Proposal.
Pursuant to the Merger Agreement, (i) Merger Sub II will merge with and into Enfusion OpCo, with Enfusion OpCo surviving the LLC Merger and becoming an indirect subsidiary of Clearwater, (ii) Merger Sub will merge with and into Enfusion,
with Enfusion surviving the Merger and becoming a direct, wholly-owned subsidiary of Clearwater